Cargando…
Hereditary hemorrhagic telangiectasia treated with low dose intravenous bevacizumab
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disorder that leads to mucocutaneous telangiectasias, epistaxis, and gastrointestinal bleeding. Depending on the severity and manifestation of the disease, various therapeutic modalities have been used, from local bleeding control...
Autores principales: | Wee, Jee Wan, Jeon, Young Woo, Eun, Jun Young, Kim, Han Jo, Bae, Sang Byung, Lee, Kyu Taek |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Society of Hematology; Korean Society of Blood and Marrow Transplantation; Korean Society of Pediatric Hematology-Oncology; Korean Society on Thrombosis and Hemostasis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4188786/ https://www.ncbi.nlm.nih.gov/pubmed/25325040 http://dx.doi.org/10.5045/br.2014.49.3.192 |
Ejemplares similares
-
Bevacizumab and gastrointestinal bleeding in hereditary hemorrhagic telangiectasia
por: Ou, George, et al.
Publicado: (2016) -
Safety of thalidomide and bevacizumab in patients with hereditary hemorrhagic telangiectasia
por: Buscarini, Elisabetta, et al.
Publicado: (2019) -
Very low dose bevacizumab for the treatment of epistaxis in patients with hereditary hemorrhagic telangiectasia
por: Thompson, Andrew B., et al.
Publicado: (2014) -
Intermittent low-dose bevacizumab in hereditary hemorrhagic telangiectasia: A case report
por: Huemer, Florian, et al.
Publicado: (2016) -
Mobile Mitral and Aortic Valvular Masses in Patients With Hereditary Hemorrhagic Telangiectasia Receiving Intravenous Bevacizumab
por: Albitar, Hasan Ahmad, et al.
Publicado: (2020)